Month: June 2026

Release – MariMed Submits DEA Registration Applications For State-Licensed Medical Cannabis Businesses

Posted on by [email protected]
Primary Logo

Research News and Market Data on MRMD

June 25, 2026 2:50pm EDTDownload as PDF

Registration Aligns With The Federal Rescheduling of Cannabis to Schedule III, Which Grants Federal Safe Harbor To Licensed Operators And Removes IRS Section 280E Restrictions

NORWOOD, Mass., June 25, 2026 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator, today announced the Company has submitted applications with the U.S. Drug Enforcement Agency (“DEA”) to register certain state-licensed medical cannabis operations. Registering the Company’s medical cannabis licenses with the DEA is a requirement to qualify for protections provided by the federal rescheduling of medical marijuana to Schedule III of the Controlled Substances Act.

“DEA registration of certain of our medical businesses marks an important step forward for MariMed as we move the Company toward becoming a federally legal business,” said MariMed CEO Jon Levine.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Company Contact:
Howard Schacter
Chief Communications Officer
Email: [email protected]
Phone: (781) 277-0007

Primary Logo

Source: MariMed Inc.

Released June 25, 2026

Release – Snail Games Unveils Upcoming PixARK: Terracrypt DLC, Highlights 2026 Steam Summer Sale Promotions, and Continued Bellwright Console Port Momentum

Posted on by [email protected]
Snail, Inc logo

Research News and Market Data on SNAL

June 25, 2026 at 1:30 PM EDT

PDF Version

CULVER CITY, Calif., June 25, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, provided an update on recent portfolio developments, including the announcement of a major new expansion for PixARK, participation in the annual 2026 Steam Summer Sale event, and continued momentum for Bellwright following its console launch.

Snail Games unveiled PixARK: Terracrypt, the first paid DLC expansion for PixARK. The upcoming DLC is planned to introduce more than 200 hours of gameplay, 80 new creatures, and a vast new environment designed to further extend player progression and exploration opportunities within the PixARK universe. PixARK has accumulated over a million downloads, and the new DLC launch aims to re-engage its community and expand the titles reach even further. In conjunction with the Steam Summer Sale, the PixARK base game is currently available at 57% off, providing new players an opportunity to experience the sandbox survival adventure ahead of the DLC’s release.

The Company also highlighted its participation in the 2026 Steam Summer Sale event, which provides players with limited time discounts. Seasonal Steam sale events have historically served as meaningful engagement drivers for Snail’s catalog, generating increased player acquisition, unit sales, and revenue contributions while expanding and re-engaging communities across established and emerging titles. As part of the promotion, ARK: Survival Ascended is available at 75% off, offering one of the deepest discounts on the title and providing an accessible entry point for new players to join the growing ARK ecosystem ahead of the July 2nd launch of Genesis Ascended Part I and Tides of Fortune content.

In addition, as part of the Steam Summer Sale event, Bellwright is also available at 34% off. The title continues to gain momentum across platforms following its console launch, maintaining a Mostly Positive user review status on Steam and earning user ratings of 3.7 stars and 3.8 stars on PlayStation and Xbox, respectively. The title also reached the Top 5 Paid Games list on Xbox, underscoring player interest as the development team delivers ongoing updates and gameplay improvements.

The Company is committed to continue supporting its portfolio through regular content updates, platform expansions, seasonal promotions, and new product launches throughout the rest of the year, including ARK: Genesis Ascended Part 1 and ARK Tides of Fortune, both currently slated for release on July 2, 2026.

For creators interested in collaborations, please reach out to [email protected]

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding the continued momentum for Bellwright following its console launch; the development team delivering ongoing updates; and continuing to support the Company’s portfolio through regular content updates, platform expansions, seasonal discounts, and new product launches throughout the remainder of the year, including ARK: Genesis Ascended Part 1 and ARK Tides of Fortune slated for release July 2, 2026; and assumptions underlying any of the foregoing. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include Snail Games’ ability to strengthen its gaming portfolio’s visibility; Snail Games’ ability to expand and grow its franchise and increase its revenue; Snail Games’ ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail, and Snail does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

Posted on by [email protected]

Research News and Market Data on NRSN

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement

Findings support continued development of PrimeC’s multi-target approach in Alzheimer’s disease

Continue Reading

CAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled proof-of-concept RoAD study (NST-AD-001) of PrimeC in Alzheimer’s disease (AD).

The RoAD clinical trial enrolled eight participants, randomized to PrimeC or placebo. Three participants completed a 12-month follow-up period, with both CSF and plasma samples collected at three timepoints.

The plasma biomarker analysis showed multiple, distinctive protein biomarker changes. Most notably, these included changes in the hallmark protein biomarkers of AD – brain-derived tau (total) and phospho-tau(s) as well as the amyloid-beta 42/40 ratio. Distinctive changes were also found in the levels of other major neurodegenerative disease misfolding proteins: alpha-synuclein (total, oligomeric and p129) and TAR DNA-binding protein 43 (“TDP-43,” both total and p409). TDP-43 is the hallmark of ALS while Parkinson’s and dementia with Lewy bodies are characterized by accumulations of alpha-synuclein. These pathological proteins commonly co-occur with Alzheimer’s disease. Either (or both) of these may be present in more than 50% of Alzheimer’s disease cases, and when co-pathology is present, it is associated with faster and/or more severe dementia. Finally, additional changes were observed in key biomarkers of oxidative stress and inflammation affecting proteostasis and neurodegeneration. All of these changes were directionally consistent with PrimeC’s proposed mechanism of action and align with biomarker effects previously observed in the Company’s ALS program, supporting engagement of shared neurodegenerative pathways.

The biomarker findings supporting PrimeC’s target engagement build on its previously reported favorable safety and tolerability profile from RoAD, in which no serious adverse events and no new or unexpected safety signals were identified.

“The initial findings seen from the RoAD study are encouraging, in that they may suggest that the same multi-target mechanism we have been advancing in ALS is engaging biology that is also central to Alzheimer’s,” said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. “This was a small, exploratory proof-of-concept study with a limited number of analyzable patient samples, and so we are appropriately measured about what it can tell us on its own. But seeing biological signals that point in the same direction across two distinct neurodegenerative diseases strengthens our conviction in PrimeC’s underlying approach and helps inform the design of a next, adequately powered study.”

“Alzheimer’s disease is driven by multiple, interacting pathological processes, which is one reason single-target therapies so often fall short. The biomarker findings in this first treated AD patient suggest broad proteostatic effects, consistent with PrimeC’s proposed mechanism of action,” said Prof. Steven E. Arnold, Professor of Neurology at Harvard Medical School and member of NeuroSense’s Scientific Advisory Board. “Of course these are the very first biomarker data of PrimeC treatment in AD and should be interpreted with that in mind. They do, however, support the rationale for evaluating PrimeC in a larger, well-controlled trial designed to test whether these biological effects replicate and more importantly, translate into meaningful clinical benefit.”

Next Steps

NeuroSense intends to use these proof-of-concept findings to help inform the design of a future, adequately powered clinical study of PrimeC in Alzheimer’s disease, and will continue engaging with scientific and regulatory stakeholders as the program advances.

About RoAD

RoAD (NST-AD-001) is a Phase 2, randomized, double-blind, placebo-controlled, exploratory proof-of-concept study evaluating the safety, tolerability, and biomarker effects of PrimeC in eight participants with Alzheimer’s disease. As a proof-of-concept study, clinical outcome measures are descriptive by design.

About Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a late-stage clinical biotechnology company focused on discovering and developing treatments for people suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, without limitation, statements regarding the interpretation, significance and potential implications of the exploratory biomarker observations from the RoAD study, the potential of PrimeC to affect disease related biology or engage mechanisms relevant to Alzheimer’s disease and the potential for these preliminary observations to inform the design of future studies. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include, without limitation, the very limited sample size and exploratory nature of the biomarker analyses reported in this press release; the risk that preliminary observations from three analyzed patients may not be predictive, may not be statistically meaningful, may not be replicated in this study or future studies and may not correlate with or translate into clinical outcomes or benefit or disease modification; risks related to the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; the risk that additional data from the RoAD study may differ from the observations reported in this press release; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

Posted on by [email protected]
Primary Logo

Research News and Market Data on MAIA

June 25, 2026 8:08am EDTDownload as PDF

Part C domestic enrollment is underway at three clinical sites in the U.S.

CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.

THIO-101 Part C patients, who are resistant to prior checkpoint inhibitor (CPI) therapy and chemotherapy, are randomized between MAIA’s proposed combination regimen of ateganosine followed by cemiplimab (Libtayo®) and treatment with ateganosine alone for two cycles. International screening was conducted in Taiwan, Turkey, Poland, Hungary, Romania and Georgia, with 41 patients enrolled and receiving treatment. The Part C study is currently screening patients at multiple clinical sites in the United States.

“We greatly appreciate the dedication and contributions of the investigators supporting our THIO-101 trial,” said Vlad Vitoc, Founder and Chief Executive Officer of MAIA Biotechnology. “With enrollment now complete at the international Part C clinical sites, we are closely monitoring patient outcomes as the data continues to mature, including key efficacy measures such as disease control rate and overall survival, which have remained central endpoints throughout the Phase 2 THIO-101 trial. Meanwhile, patient screening is ongoing at three activated clinical sites in the United States.”

In Parts A and B of THIO-101, MAIA reported data showing median survival of 17.8 months. Overall survival (OS) beyond two years was observed for eight patients in Parts A and B of THIO-101; the patients did not receive subsequent lines of therapy. One patient in this cohort receiving 3L therapy has survived for over 33 months. Expected survival in this heavily pre-treated population is 5.8 months.1

The FDA has granted Fast Track designation for ateganosine in NSCLC treatment, potentially expediting the regulatory process to a potential Accelerated Approval and Priority Review.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

1 Girard N, et al. J Thorac Onc 2009;12:1544-1549

Primary Logo

Source: MAIA Biotechnology, Inc.

Released June 25, 2026

Crypto Has Lost More Than Half Its Value in Eight Months

Posted on by [email protected]

The crypto market is in the middle of one of the most sustained drawdowns in its history, and there is no clear sign it has found a bottom. The total market capitalization of cryptocurrency has erased more than half its value in just eight months. After peaking at a record $4.3 trillion on October 6, 2025, the total crypto market is now worth approximately $2.0 trillion — a 54% decline over 261 days. That works out to an average of roughly $8.8 billion in value erased every single day for nearly nine consecutive months.

Bitcoin, the sector’s bellwether, is trading just below $59,200, down nearly 1% on the session and well off the highs above $100,000 it commanded earlier in this cycle.

Why the Selloff Makes Sense

The pullback, while severe, is not difficult to explain. Crypto is among the highest-risk, most speculative asset classes in the market, and the macro environment of 2026 has been actively hostile to risk. Inflation running at 4.2%, a Federal Reserve under new chair Kevin Warsh that has dropped its easing bias and signaled potential rate hikes before year-end, persistent geopolitical tension from the Iran conflict, and a broad repricing of stretched valuations across speculative assets have all weighed heavily on the space. Crypto has become increasingly sensitive to interest rate expectations, and a higher-for-longer rate environment removes much of the cheap, abundant risk capital that fueled prior bull runs.

There is also a competition-for-capital dynamic worth noting. The wave of high-profile AI IPOs in 2026 — Cerebras, SpaceX, and the anticipated Anthropic and OpenAI listings — has absorbed an enormous amount of the speculative risk capital that historically flowed into crypto during bull cycles. When investors can buy generational growth stories in the public markets, the appetite for digital assets diminishes.

The Case for Patience

Not everyone views the current drawdown as a reason to abandon the space. A long-cycle perspective on crypto notes that winters have repeatedly come and gone while the underlying industry continued to grow — the prior cycle bottomed near $16,000 four years ago, which makes the current $60,000 level appear relatively elevated by historical standards. The bull case from here rests on a familiar set of catalysts: clearer regulatory market structure, favorable legislation, continued development of real-world use cases, and the eventual return of risk capital once the current wave of AI companies completes their public offerings and post-IPO share lockups expire. Whether those catalysts materialize on any near-term timeline remains the central open question.

The Equity Market Alternative

For investors, the crypto drawdown raises a practical question worth considering: why attempt to time a bottom in one of the market’s most volatile asset classes when public equities are offering clear, fundamentals-driven opportunities? The contrast is stark. While crypto sheds billions daily, companies tied to the AI infrastructure buildout — including memory and semiconductor names posting blowout earnings and raising guidance — are demonstrating measurable revenue growth and expanding margins.

This is not a dismissal of crypto’s long-term potential, which remains a genuine debate. But for investors focused on opportunities grounded in earnings, cash flow, and visible demand, the public markets — including the small and microcap names feeding the AI supply chain — currently offer compelling alternatives that do not require catching a falling knife. Sometimes the better opportunity is the one hiding in plain sight.

Tectonic Metals Inc. (TETOF) – Alaska’s Next Tier One Gold Deposit?

Posted on by [email protected]


Thursday, June 25, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. We are initiating coverage of Tectonic Metals Inc. with an Outperform rating and price target of US$3.50 (C$4.85) per share. In our view, Tectonic’s Flat Gold Project, located in the prolific Kuskokwim Mineral Belt in Alaska, offers the potential to become a Tier 1 gold mine which are generally defined as those producing at least 500 thousand gold ounces per year, exhibit a mine life of 10+ years, with costs in the lower half of the global industry cost curve. Based on drilling results to date, we estimate a potential mineral endowment of at least 5.3 million gold ounces with significant growth prospects. Tectonic expects to publish an initial resource estimate in the first quarter of 2027.

Exploration and drilling program yields significant discoveries. Drilling at the Flat Gold Project continues to demonstrate scale, with mineralization at the Chicken Mountain target now defined over approximately 3.3 kilometers of strike length, widths of up to 700 meters, and depths exceeding 300 meters while remaining open in all directions. All 191 holes drilled at Chicken Mountain have intersected gold mineralization, with 117 of 191 holes ending in mineralization.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – The Transformation Takes Shape

Posted on by [email protected]


Thursday, June 25, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercialization phase begins. Following several years of portfolio repositioning and infrastructure investment, Xcel has begun commercializing its next generation of creator-led brands, marking a transition from strategy development to revenue execution.

Creator-commerce platform differentiates the investment story. Unlike traditional consumer products companies, Xcel leverages established creators with highly engaged audiences to develop brands across Fashion, Food & Beverage, Pet, and Home, creating an asset-light, royalty-driven business model with meaningful operating leverage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NeuroSense Therapeutics Ltd. (NRSN) – Phase 2 RoAD Trial Findings In Alzheimer’s Disease Reported

Posted on by [email protected]


Thursday, June 25, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Supports Mechanism of Action. NeuroSense reported data from its Phase 2 RoAD trial testing PrimeC in Alzheimer’s Disease (AD). The study was designed to evaluate safety, efficacy, and disease-associated biomarkers. The results showed changes consistent with the prevention of degeneration and neuronal cell death. We believe these data support PrimeC’s mechanism and its benefits, providing proof of concept for further studies.

Study Design. The Phase 2 RoAD trial was a placebo-controlled study testing PrimeC in Alzheimer’s disease. The trial enrolled eight patients who were randomized to receive PrimeC or placebo for 52 weeks. Three participants completed a 12-month follow-up period, with CSF and plasma samples evaluated at three timepoints.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – AI Launch Supports Transformation

Posted on by [email protected]


Thursday, June 25, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

The launch of the AI-powered Next Generation CX Platform reinforces strategic transformation. Conduent introduced new AI-enabled capabilities, including real-time translation, AI-driven agent training, and voice enhancement technologies, further positioning the company as a technology-enabled customer experience provider rather than a traditional business process outsourcer.

New capabilities support higher-margin, technology-enabled growth. The platform enables real-time translation across more than 90 languages, AI-based training simulations that can reduce agent onboarding time by up to 40%, and accent smoothing and noise cancellation, all of which enhance customer interactions and improve operational efficiency.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Small Cap Biotech Is Where the Catalysts Are Right Now

Posted on by [email protected]

While the broader market spent June fixated on the SpaceX IPO, the Federal Reserve transition, and a chip-driven selloff, something quieter and arguably more consequential has been building in small cap biotech. Over the past several weeks, the sector has produced a steady stream of value-moving catalysts — reverse mergers, patent wins, acquisitions at steep premiums, and AI partnerships — that collectively point to one of the most active catalyst environments the space has seen in years. For investors who understand how small cap biotech actually creates value, that activity is worth paying close attention to.

A Cluster of Catalysts in a Single Month

The pace has been striking. On Tuesday alone, three separate small cap biotech stories moved sharply. Boundless Bio surged roughly 75% after announcing a reverse merger with privately held Serapha Bio, pivoting the public company toward a gene editing therapy for a serious inherited disease while distributing excess cash to existing shareholders. CervoMed soared 61% on a key patent win for its dementia drug candidate. Butterfly Network jumped 33% on an expanded medical imaging partnership with AI company Midjourney.

Those single-day moves did not happen in isolation. Earlier in June, GSK agreed to acquire Nuvalent for $10.6 billion — a 40% premium — to gain access to its precision lung cancer pipeline. AbbVie followed with a $10.9 billion all-cash acquisition of immunology drug maker Apogee Therapeutics. Each of these transactions reflects the same underlying dynamic playing out at different scales.

Why Catalysts Concentrate in Small Cap Biotech

Unlike most sectors, where stock prices tend to move incrementally with earnings and macro conditions, small cap biotech is fundamentally a catalyst-driven asset class. A clinical-stage company often has no revenue and no approved products. Its entire value rests on the probability-weighted potential of its pipeline — and that value can reprice dramatically and instantly when a binary event occurs.

Those events take predictable forms. FDA decisions and breakthrough designations validate a drug’s regulatory path. Clinical trial data readouts confirm or refute a therapy’s efficacy. Patent rulings protect or expose a company’s competitive position. Acquisitions by large pharmaceutical companies crystallize value at a premium. And reverse mergers transform a stalled public shell into a vehicle for a more promising private asset. Each of these can move a small cap biotech 30%, 50%, or more in a single session — moves that simply do not happen with the same frequency or magnitude anywhere else in the public markets.

The Structural Forces Behind the Surge

The current wave is being driven by forces that are unlikely to reverse soon. Large pharmaceutical companies are facing significant patent cliffs over the next several years and are aggressively acquiring external innovation to replace expiring revenue. The pipeline of clinical-stage companies with validated assets in the sub-$2 billion market cap range remains deep. And next-generation technologies — gene editing, precision oncology, AI-enabled diagnostics — are moving from theoretical promise toward clinical proof of concept, creating fresh acquisition and partnership targets.

For investors, the takeaway is not that every small cap biotech is a winner. The opposite is true: the same binary nature that produces enormous gains also produces sharp losses when trials fail or approvals are denied. The risk is real and concentrated. But the catalyst density in this corner of the market is exactly what makes it one of the most closely watched spaces in small cap investing right now. The companies producing these moves were, in many cases, trading well below the radar of mainstream coverage just weeks ago.

That is precisely where the most significant repricing tends to happen first.

Release – Conduent Introduces AI-Powered Next Generation CX Platform to Expand Global Customer Reach and Accelerate Agent Performance

Posted on by [email protected]

Research News and Market Data on CNDT

June 24, 2026

Customer Experience Commercial Sector

New capabilities combine real-time translation, AI-driven training simulation and voice enhancement technologies to improve customer satisfaction and help organizations scale service delivery globally

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today introduced new AI-powered capabilities within its Next Generation CX Platform designed to help organizations overcome language barriers, accelerate agent readiness and improve customer interactions. The platform combines real-time translation, AI-driven training simulation and voice enhancement technologies to help clients expand into new markets, improve service quality and increase customer satisfaction.

The Next Generation CX Platform is comprised of modular solutions that leverage AI, automation and advanced analytics to optimize customer interactions, enhance agent performance, improve contact center operations and generate actionable insights. Together, these capabilities help organizations deliver more consistent, personalized and efficient customer experiences across channels and geographies.

Real-Time Translation Helps Organizations Reach More Customers

As organizations expand globally, delivering support in customers’ preferred languages can be costly and complex. Recruiting multilingual agents, relying on interpreters or routing customers through multiple touchpoints can increase costs and create friction in the customer experience.

Conduent’s AI-powered real-time translation solution helps remove those barriers by enabling seamless conversations between customers and agents across more than 90 languages. Customers receive support in their preferred language while organizations continue to leverage their existing agent workforce and subject matter expertise. The solution enables organizations to expand into new markets more quickly while maintaining a consistent, high-quality customer experience.

AI-Powered Training Accelerates Agent Readiness

Effective training is critical to delivering exceptional customer service. Conduent’s AI-driven training simulation solution enables agents to practice realistic customer scenarios and receive targeted coaching based on analysis of voice, chat and screen interactions.

The solution provides consistent training experiences across languages and globally distributed teams, helping organizations onboard agents more efficiently and maintain service quality at scale. For clients with seasonal or cyclical customer service demands, such as tax season or holiday peaks, the solution can accelerate time to proficiency by up to 40%, enabling agents to become customer-ready faster.

Voice Enhancement Improves Customer Interactions

Conduent is also introducing AI-powered accent smoothing and noise cancellation capabilities to improve the clarity and effectiveness of customer-agent conversations. By reducing communication barriers and minimizing background distractions, these technologies help improve customer engagement, increase interaction quality and support faster issue resolution. The result is a more seamless customer experience and greater confidence in every interaction.

“The future of customer experience isn’t AI or people, it’s AI and people working together,” said George Wehbe, President, Commercial Solutions at Conduent. “Our Next Generation CX Platform has arrived. It helps clients reach more customers, onboard agents faster and deliver more consistent service across languages and geographies. By combining AI-powered automation with experienced agents, we’re helping organizations improve customer satisfaction while scaling more efficiently.”

About Conduent’s Next Generation CX Platform

Conduent’s Next Generation CX Platform combines AI-powered automation, agent enablement, operational intelligence and customer insights into a flexible suite of solutions that can be deployed across the customer experience lifecycle. The platform is designed to help organizations improve customer outcomes, increase operational efficiency and adapt to evolving customer expectations while maintaining the human expertise required to resolve complex issues and build long-term loyalty.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

Remy Kaul

Conduent

[email protected]

Release – Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Posted on by [email protected]

Research News and Market Data on CVKD

Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT)

First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals

Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market

PONTE VEDRA, Fla., June 24, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that late-breaking clinical data on its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005 (formerly VLX-1005), have been accepted for a prestigious oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH). The congress will be held live and onsite from July 11-15, 2026, at the Palais des Congrès de Paris in Paris, France.

The abstract, titled “12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia,” was selected by expert peer reviewers for inclusion in the high-profile session on clinical trials and breakthrough innovations.

“The selection of our Phase 2 CAD-1005 study for a late-breakthrough oral presentation at ISTH is another milestone underscoring the scientific integrity and commercial importance of our pipeline,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “Heparin-Induced Thrombocytopenia represents a high-value therapeutic market with significant unmet needs and no approved therapies that target the specific underlying immune mechanisms of HIT. This presentation offers an elite global platform to showcase the clinical potential of CAD-1005.”

“Targeting 12-lipoxygenase is a novel, highly selective therapeutic approach that addresses the root cause of immune-mediated platelet activation in HIT,” added Dr. Steve McKenzie, Professor of Medicine at Thomas Jefferson University, the principal investigator and presenter. “The data we are presenting live in Paris – the first-ever randomized, blinded, placebo-controlled trial in HIT – illustrate how CAD-1005 could fundamentally shift the treatment paradigm for acute thrombotic care and may, if approved, offer a highly differentiated option for these high-risk patients.”

Presentation Details:

  • Session Title: Late-Breakthrough Abstracts I: Clinical Trials and Innovation in Thrombosis
  • Abstract Title: 12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia
  • Date: July 12, 2026
  • Session Time: 11:15 AM – 12:00 PM CEST

For additional details regarding the scientific program, please visit the ISTH Congress Official Website.

About Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated, prothrombotic adverse drug reaction in which antibodies against platelet factor 4-heparin complexes activate platelets via FcγRIIA receptors, triggering a cascade that can lead to life-threatening thrombosis. Current management relies on non-heparin anticoagulants, which reduce thrombin generation but do not directly address the underlying antibody-mediated platelet activation; new thrombosis remains a major clinical concern even with appropriate anticoagulant therapy.

About CAD-1005

CAD-1005 is a novel investigational therapeutic under development for the treatment of heparin-induced thrombocytopenia (HIT). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling associated with HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that contribute to disease progression.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease, those with left ventricular assist devices, and potentially, those with Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, and the leading cause of acquired heart disease in developed countries.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements regarding the late-breakthrough oral presentation at ISTH being a significant milestone that supports the scientific integrity and commercial importance of the Company’s pipeline and the data being presented illustrating how CAD-1005 could fundamentally shift the treatment paradigm for acute thrombotic care, and may, if approved, offer a highly differentiated option for these high-risk patient patients and CAD-1005 being intended to be used in conjunction with existing standards of care and is being developed to address the underlying biological mechanisms contributing to disease progression.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to raise sufficient capital to continue progress of CAD-1005; the ability to advance directly to Phase 3 study evaluating CAD-1005 in patients with HIT; the ability to successfully design and complete the Phase 3 study and derive the results needed for an NDA submission; and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, [email protected]

Russell Reconstitution Day Approaches: Small Caps Prepare for a Surge in Trading Activity

Posted on by [email protected]

The annual Russell Index reconstitution becomes official after the market closes on Friday, June 26, setting the stage for one of the busiest trading sessions of the year for small-cap stocks.

While the event occurs every June, this year’s reconstitution arrives amid renewed investor interest in small caps and follows a strong first half for many emerging growth companies. As index funds and ETFs rebalance portfolios to reflect the new membership lists, millions of shares are expected to change hands during Friday’s closing auction.

For companies being added to the Russell 2000 and Russell Microcap indexes, inclusion can provide increased visibility, improved liquidity, and exposure to a broader institutional investor base.

Hundreds of Companies Set to Join Russell Indexes

FTSE Russell’s preliminary lists show hundreds of companies scheduled for addition across the Russell index family. The Russell 2000 is expected to add more than 200 companies, while numerous smaller firms will enter the Russell Microcap Index.

Several notable additions have already attracted investor attention, particularly among healthcare, technology, industrial, and defense-related companies. Healthcare remains the largest source of new additions, reflecting the continued recovery in small-cap biotech valuations. Technology and industrial companies also represent a significant portion of new constituents.

Why Friday Matters

The actual reconstitution occurs during the closing auction on Friday, often producing extraordinary trading volumes in affected stocks.

Passive funds tracking Russell indexes must adjust their holdings to match the updated index composition. This creates concentrated buying in newly added companies and selling in stocks being removed.

For some smaller companies, the volume traded during the closing auction can exceed multiple days’ worth of normal trading activity.

Historically, stocks scheduled for inclusion often experience elevated volume leading into reconstitution day as traders attempt to position ahead of index fund purchases. The largest impact, however, typically occurs during the final minutes of trading on the effective date.

Institutional Visibility Can Be a Catalyst

Although index inclusion does not change a company’s fundamentals, it can increase awareness among institutional investors that may have previously overlooked the stock.

For smaller companies, particularly those transitioning from micro-cap status, Russell inclusion often serves as a milestone. Increased liquidity can improve trading efficiency, broaden ownership, and potentially attract additional analyst coverage.

Investors should remember that index inclusion alone rarely drives long-term performance. Ultimately, earnings growth, execution, and capital allocation remain the primary determinants of shareholder returns.

Looking Beyond Reconstitution Day

Once Friday’s rebalance is complete, attention will shift from index mechanics back to fundamentals.

Nevertheless, Russell reconstitution remains one of the most important annual events for the small-cap market. For investors, it provides a snapshot of which companies have achieved sufficient scale and market value to earn inclusion in one of the most widely followed small-cap benchmarks.

As the closing bell approaches on Friday, traders and portfolio managers alike will be watching closely as billions of dollars are repositioned across the small-cap landscape.

Notable Companies Joining the Russell Indexes

This year’s reconstitution includes companies from a wide range of industries, underscoring the diversity of today’s small-cap market. Among the companies expected to be added to the Russell indexes are Conduent (NASDAQ: CNDT), Star Equity Holdings (NASDAQ: STRR), The Beachbody Company (NYSE: BODI), Vince Holding Corp. (NYSE: VNCE), Commercial Vehicle Group (NASDAQ: CVGI), FreightCar America (NASDAQ: RAIL), Ocugen (NASDAQ: OCGN), Twin Disc (NASDAQ: TWIN), and Unicycive Therapeutics (NASDAQ: UNCY).

The additions span sectors including business services, industrials, consumer discretionary, transportation, healthcare, and technology. Russell membership is determined through FTSE Russell’s annual reconstitution process, which ranks eligible U.S. companies by market capitalization and other index criteria. The final index changes become effective after the market closes on June 27.